Evaluation of clinical formalin-fixed paraffin-embedded tissue quality for targeted-bisulfite sequencing.


Journal

Pathology international
ISSN: 1440-1827
Titre abrégé: Pathol Int
Pays: Australia
ID NLM: 9431380

Informations de publication

Date de publication:
Feb 2021
Historique:
received: 29 07 2020
revised: 28 10 2020
accepted: 16 11 2020
pubmed: 18 12 2020
medline: 26 10 2021
entrez: 17 12 2020
Statut: ppublish

Résumé

Formalin-fixed paraffin-embedded (FFPE) tissues are promising biological resources for genetic research. Recent improvements in DNA extraction from FFPE samples allowed the use of these tissues for multiple sequencing methods. However, fundamental research addressing the application of FFPE-derived DNA for targeted-bisulfite sequencing (TB-seq) is lacking. Here, we evaluated the suitability of FFPE-derived DNA for TB-seq. We conducted TB-seq using FFPE-derived DNA and corresponding fresh frozen (FF) tissues of patients with kidney cancer and compared the quality of DNA, libraries, and TB-seq statistics between the two preservation methods. The approximately 600-bp average fragment size of the FFPE-derived DNA was significantly shorter than that of the FF-derived DNA. The sequencing libraries constructed using FFPE-derived DNA and the mapping ratio were approximately 10 times and 10% lower, respectively, than those constructed using FF-derived DNA. In the mapped data of FFPE-derived DNA, duplicated reads accounted for > 60% of the obtained sequence reads, with lower mean on-target coverage. Therefore, the standard TB-seq protocol is inadequate for obtaining high-quality data for epigenetic analysis from FFPE-derived DNA, and technical improvements are necessary for enabling the use of archived FFPE resources.

Identifiants

pubmed: 33333623
doi: 10.1111/pin.13054
pmc: PMC7898333
doi:

Substances chimiques

Fixatives 0
Sulfites 0
Formaldehyde 1HG84L3525
DNA 9007-49-2
hydrogen sulfite OJ9787WBLU

Types de publication

Comparative Study Evaluation Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

135-140

Subventions

Organisme : Japan Agency for Medical Research and Development
ID : JP17km0105004

Informations de copyright

© 2020 The Authors. Pathology International published by Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.

Références

JCO Precis Oncol. 2018;2018:
pubmed: 29862382
BMC Med Genomics. 2011 Sep 29;4:68
pubmed: 21958464
Pathol Int. 2018 Nov;68(11):633-635
pubmed: 30239063
Clin Epigenetics. 2017 Apr 4;9:33
pubmed: 28392843
Histol Histopathol. 2011 Jun;26(6):797-810
pubmed: 21472693
NPJ Genom Med. 2017 Apr 13;2:11
pubmed: 29263827
Pathol Int. 2018 Feb;68(2):63-90
pubmed: 29431262
Pract Lab Med. 2020 Feb 03;19:e00153
pubmed: 32123717
PLoS One. 2019 Apr 11;14(4):e0211400
pubmed: 30973937
Hum Genome Var. 2018 Mar 29;5:18008
pubmed: 29619235
Circ Genom Precis Med. 2020 Feb;13(1):e002649
pubmed: 31928219
BMC Genomics. 2015 Nov 03;16:892
pubmed: 26531060
Oncotarget. 2015 Sep 22;6(28):25943-61
pubmed: 26305677
Cell Oncol. 2004;26(5-6):329-34
pubmed: 15623943
BMC Med Genomics. 2017 Aug 31;10(1):54
pubmed: 28859641
Brief Funct Genomics. 2016 Nov;15(6):399-407
pubmed: 27107288
PLoS One. 2015 Dec 07;10(12):e0144162
pubmed: 26641479

Auteurs

Hideki Ohmomo (H)

Iwate Tohoku Medical Megabank Organization, Iwate Medical University, 1-1-1 Idaidori, Yahaba, Shiwa, Iwate, 028-3694, Japan.

Shohei Komaki (S)

Iwate Tohoku Medical Megabank Organization, Iwate Medical University, 1-1-1 Idaidori, Yahaba, Shiwa, Iwate, 028-3694, Japan.

Kanako Ono (K)

Iwate Tohoku Medical Megabank Organization, Iwate Medical University, 1-1-1 Idaidori, Yahaba, Shiwa, Iwate, 028-3694, Japan.

Yoichi Sutoh (Y)

Iwate Tohoku Medical Megabank Organization, Iwate Medical University, 1-1-1 Idaidori, Yahaba, Shiwa, Iwate, 028-3694, Japan.

Tsuyoshi Hachiya (T)

Iwate Tohoku Medical Megabank Organization, Iwate Medical University, 1-1-1 Idaidori, Yahaba, Shiwa, Iwate, 028-3694, Japan.

Eri Arai (E)

Department of Pathology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.
Division of Molecular Pathology, National Cancer Center Research Institute, 5-1-1, Tsukiji, Chuo, Tokyo, 104-0045, Japan.

Hiroyuki Fujimoto (H)

Department of Urology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo, Tokyo, 104-0045, Japan.

Teruhiko Yoshida (T)

Department of Clinical Genomics, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo, Tokyo, 104-0045, Japan.

Yae Kanai (Y)

Department of Pathology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.
Division of Molecular Pathology, National Cancer Center Research Institute, 5-1-1, Tsukiji, Chuo, Tokyo, 104-0045, Japan.

Makoto Sasaki (M)

Iwate Tohoku Medical Megabank Organization, Iwate Medical University, 1-1-1 Idaidori, Yahaba, Shiwa, Iwate, 028-3694, Japan.
Division of Ultrahigh Field MRI, Institute for Biomedical Sciences, Iwate Medical University, 1-1-1 Idaidori, Yahaba, Shiwa, Iwate, 028-3694, Japan.

Atsushi Shimizu (A)

Iwate Tohoku Medical Megabank Organization, Iwate Medical University, 1-1-1 Idaidori, Yahaba, Shiwa, Iwate, 028-3694, Japan.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH